WallStSmart

Boston Scientific Corp (BSX)vsEnbridge Inc (ENB)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Enbridge Inc generates 225% more annual revenue ($65.19B vs $20.07B). BSX leads profitability with a 14.4% profit margin vs 11.5%. BSX appears more attractively valued with a PEG of 0.75. ENB earns a higher WallStSmart Score of 67/100 (B-).

BSX

Buy

63

out of 100

Grade: C+

Growth: 8.0Profit: 6.5Value: 8.7Quality: 5.5
Piotroski: 4/9

ENB

Strong Buy

67

out of 100

Grade: B-

Growth: 5.3Profit: 6.5Value: 10.0Quality: 4.5
Piotroski: 3/9Altman Z: 0.61
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

BSXUndervalued (+1.2%)

Margin of Safety

+1.2%

Fair Value

$70.62

Current Price

$69.78

$0.84 discount

UndervaluedFair: $70.62Overvalued
ENBUndervalued (+53.1%)

Margin of Safety

+53.1%

Fair Value

$109.98

Current Price

$54.48

$55.50 discount

UndervaluedFair: $109.98Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BSX4 strengths · Avg: 8.3/10
Market CapQuality
$101.28B9/10

Large-cap with strong market position

PEG RatioValuation
0.758/10

Growing faster than its price suggests

Revenue GrowthGrowth
15.9%8/10

15.9% revenue growth

Free Cash FlowQuality
$1.01B8/10

Generating 1.0B in free cash flow

ENB3 strengths · Avg: 9.0/10
Debt/EquityHealth
0.1010/10

Conservative balance sheet, low leverage

Market CapQuality
$116.68B9/10

Large-cap with strong market position

Price/BookValuation
2.9x8/10

Reasonable price relative to book value

Areas to Watch

BSX1 concerns · Avg: 4.0/10
P/E RatioValuation
35.1x4/10

Premium valuation, high expectations priced in

ENB4 concerns · Avg: 3.3/10
PEG RatioValuation
1.824/10

Expensive relative to growth rate

EPS GrowthGrowth
2.9%4/10

2.9% earnings growth

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Altman Z-ScoreHealth
0.612/10

Distress zone — elevated risk

Comparative Analysis Report

WallStSmart Research

Bull Case : BSX

The strongest argument for BSX centers on Market Cap, PEG Ratio, Revenue Growth. Revenue growth of 15.9% demonstrates continued momentum. PEG of 0.75 suggests the stock is reasonably priced for its growth.

Bull Case : ENB

The strongest argument for ENB centers on Debt/Equity, Market Cap, Price/Book.

Bear Case : BSX

The primary concerns for BSX are P/E Ratio.

Bear Case : ENB

The primary concerns for ENB are PEG Ratio, EPS Growth, Piotroski F-Score.

Key Dynamics to Monitor

BSX profiles as a growth stock while ENB is a value play — different risk/reward profiles.

ENB carries more volatility with a beta of 0.86 — expect wider price swings.

BSX is growing revenue faster at 15.9% — sustainability is the question.

BSX generates stronger free cash flow (1.0B), providing more financial flexibility.

Bottom Line

ENB scores higher overall (67/100 vs 63/100). Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Boston Scientific Corp

HEALTHCARE · MEDICAL DEVICES · USA

Boston Scientific Corporation, doing business as Boston Scientific, is a manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.

Enbridge Inc

ENERGY · OIL & GAS MIDSTREAM · USA

Enbridge Inc. is an energy infrastructure company. The company is headquartered in Calgary, Canada.

Want to dig deeper into these stocks?